Fig. 7

Co-effects of miR-138-5p and SOX13; SOX13 promoted transcription of FUS forming a feedback loop. (a-b) The co-effects of miR-138-5p and SOX13 on the expression levels of SPON2 were evaluated by qRT-PCR and western blot. Data are presented as the means ± SD (n = 3, each group). ^*P < 0.05, ^**P < 0.01 vs. miR-138-5p(+)NC + SOX13(+)NC group. ^##P < 0.01 vs. miR-138-5p(+) + SOX13(+)NC group. (c) The co-effects of miR-138-5p and SOX13 on the viability of GECs were evaluated by the CCK8 assay. Data are presented as the means ± SD (n = 5, each group). ^**P < 0.01 vs. miR-138-5p(+)NC + SOX13(+)NC group; ^##P < 0.01 vs. miR-138-5p(+) + SOX13(+)NC group. (d) The co-effects of miR-138-5p and SOX13 on the migration of GECs were evaluated by the transwell assay. Data are presented as the means ± SD (n = 5, each group). ^**P < 0.01 vs. miR-138-5p(+)NC + SOX13(+)NC group; ^##P < 0.01 vs. miR-138-5p(+) + SOX13(+)NC group. The scale bar represents 100 μm. (e) The co-effects of miR-138-5p and SOX13 on the tube formation of GECs were evaluated by the Matrigel tube formation assay. Data are presented as the means ± SD (n = 5, each group). ^*P < 0.05, ^**P < 0.01 vs. miR-138-5p(+)NC + SOX13(+)NC group; ^##P < 0.01 vs. miR-138-5p(+) + SOX13(+)NC group. The scale bar represents 100 μm. (f) Schematic representation of the human FUS promoter region 3000 bp upstream or 200 bp downstream of the TSS, designated as + 1. ChIP PCR products for the putative SOX13 binding site and an upstream region not expected to associate with SOX13 are depicted with bold lines. (g-h) The qRT-PCR and western blot analysis of SOX13 regulation of the expression levels of FUS. Values are presented as the means ± SD (n = 3, each group). ^**P < 0.01 vs. SOX13(+)NC group; ^##P < 0.01 vs. SOX13(−)NC group